BLCO · Bausch + Lomb Corporation
$15.98
+0.19% last session
End-of-day data · updated 2026-07-25
Market cap
$6B
Enterprise value
$11B
Trailing P/E
—
Forward P/E
15.1
Dividend yield
—
Beta
0.56
Avg volume
0M
Employees
13K
2D change
1.19%
5D change
1.19%
10D change
-0.68%
30D change
1.63%
60D change
2.47%
MTD change
-2.30%
YTD change
-5.33%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — BLCO
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-28
Latest call per bank · past 12 months
UBS
Buy$21.00
+31.4% vs priceCitigroup
Buy$21.00
+31.4% vs priceBarclays
Equal-Weight$20.00
+25.2% vs priceWells Fargo
Equal-Weight$18.00
+12.6% vs priceMorgan Stanley
Overweight$21.00
+31.4% vs priceRBC Capital
Outperform$19.00
+18.9% vs priceJP Morgan
Neutral$16.00
+0.1% vs priceGoldman Sachs
Neutral$16.00
+0.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-28 | UBS | Initiates | Buy | $0.00 → $21.00 |
| 2026-07-06 | Evercore ISI Group | Maintains | In-Line | $16.00 → $17.00 |
| 2026-04-30 | Evercore ISI Group | Maintains | In-Line | $17.00 → $16.00 |
| 2026-04-06 | Evercore ISI Group | Maintains | In-Line | $17.50 → $17.00 |
| 2026-02-23 | HC Wainwright & Co. | Maintains | Buy | $17.00 → $20.00 |
| 2026-02-19 | Citigroup | Maintains | Buy | $20.00 → $21.00 |
| 2026-02-19 | Barclays | Maintains | Equal-Weight | $17.00 → $20.00 |
| 2026-02-19 | Stifel | Maintains | Hold | $15.00 → $16.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-23
- RSI (14): RSI is 48 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 0.6% above the 50-day MA ($15.88).
- Price vs 200-day MA: Trading 1.8% below the 200-day MA ($16.28).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.09) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($13.50) and high ($18.60).
BLCO Price Chart
Loading chart for BLCO…
Fundamentals
About Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
More in Medical Instruments & Supplies
ISRG
Intuitive Surgical, Inc.
$121B -40.4% YTD
MDLN
Medline Inc.
$69B -7.7% YTD
BDX
Becton, Dickinson and Company
$43B 3.9% YTD
ALC
Alcon Inc.
$33B -13.4% YTD
RMD
ResMed Inc.
$28B -18.5% YTD
WST
West Pharmaceutical Services, I
$23B 19.5% YTD
COO
The Cooper Companies, Inc.
$14B -14.2% YTD
SOLV
Solventum Corporation
$14B -1.6% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.